Justus B Cohen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7759273/publications.pdf

Version: 2024-02-01

69 papers	3,149 citations	136950 32 h-index	155660 55 g-index
70 all docs	70 docs citations	70 times ranked	2636 citing authors

#	Article	IF	Citations
1	Evaluation of parameters for efficient purification and long-term storage of herpes simplex virus-based vectors. Molecular Therapy - Methods and Clinical Development, 2022, 26, 132-143.	4.1	3
2	Oncolytic HSV Vectors and Anti-Tumor Immunity. Current Issues in Molecular Biology, 2021, 41, 381-468.	2.4	8
3	Abstract PO089: Comparison of Two oHSV Vectors for the Treatment of Glioblastoma. , 2021, , .		0
4	Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment. Molecular Therapy - Oncolytics, 2021, 22, 444-453.	4.4	1
5	Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRÎ±1 for Specific Infection of Breast Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 8815.	4.1	7
6	Protocol Optimization for the Production of the Non-Cytotoxic JÎ”NI5 HSV Vector Deficient in Expression of Immediately Early Genes. Molecular Therapy - Methods and Clinical Development, 2020, 17, 612-621.	4.1	5
7	Engineering HSV-1 Vectors for Gene Therapy. Methods in Molecular Biology, 2020, 2060, 73-90.	0.9	17
8	Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies. Molecular Therapy - Methods and Clinical Development, 2020, 16, 145-154.	4.1	15
9	Cellular Antisilencing Elements Support Transgene Expression from Herpes Simplex Virus Vectors in the Absence of Immediate Early Gene Expression. Journal of Virology, 2018, 92, .	3.4	12
10	Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens. Current Cancer Drug Targets, 2018, 18, 162-170.	1.6	16
11	Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock	2.5	40
12	Engineered HSV vector achieves safe long-term transgene expression in the central nervous system. Scientific Reports, 2017, 7, 1507.	3.3	27
13	Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes. Molecular Therapy - Methods and Clinical Development, 2017, 6, 79-90.	4.1	14
14	An HSV-based library screen identifies PP1Î± as a negative TRPV1 regulator with analgesic activity in models of pain. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16040.	4.1	9
15	Retargeting of herpes simplex virus (HSV) vectors. Current Opinion in Virology, 2016, 21, 93-101.	5.4	24
16	Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus. Journal of Virology, 2016, 90, 11096-11105.	3.4	8
17	Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread. Gene Therapy, 2016, 23, 479-488.	4.5	30
18	Constitutive Expression of GATA4 Dramatically Increases the Cardiogenic Potential of D3 Mouse Embryonic Stem Cells. Open Biotechnology Journal, 2016, 10, 248-257.	1.2	7

#	Article	IF	Citations
19	Moving toward a gene therapy for Huntingtonâ€™s disease. Gene Therapy, 2015, 22, 931-933.	4.5	17
20	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Scientific Reports, 2015, 5, 11483.	3.3	270
21	Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1632-41.	7.1	51
22	Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV. Molecular Therapy, 2015, 23, 99-107.	8.2	69
23	Engineering HSV-1 Vectors for Gene Therapy. Methods in Molecular Biology, 2014, 1144, 63-79.	0.9	51
24	Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Molecular Therapy - Oncolytics, 2014, 1, 14010.	4.4	33
25	Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. Gene Therapy, 2013, 20, 761-769.	4.5	12
26	Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-retargeted Oncolytic Herpes Simplex Virus. Molecular Therapy, 2013, 21, 561-569.	8.2	94
27	Novel Mutations in gB and gH Circumvent the Requirement for Known gD Receptors in Herpes Simplex Virus 1 Entry and Cell-to-Cell Spread. Journal of Virology, 2013, 87, 1430-1442.	3.4	27
28	Gene therapy for the treatment of chronic peripheral nervous system pain. Neurobiology of Disease, 2012, 48, 255-270.	4.4	51
29	Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus. Advances in Virology, 2012, 2012, 1-10.	1.1	10
30	Mechanism of HSV infection through soluble adapter-mediated virus bridging to the EGF receptor. Virology, 2011, 413, 12-18.	2.4	12
31	Bispecific Adapter-Mediated Retargeting of a Receptor-Restricted HSV-1 Vector to CEA-Bearing Tumor Cells. Molecular Therapy, 2011, 19, 507-514.	8.2	20
32	Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells. Veterinary Microbiology, 2010, 141, 12-21.	1.9	35
33	Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Therapy, 2010, 17, 1200-1205.	4.5	40
34	A Herpes Simplex Virus Vector System for Expression of Complex Cellular cDNA Libraries. Journal of Virology, 2010, 84, 7360-7368.	3.4	11
35	A Double Mutation in Glycoprotein gB Compensates for Ineffective gD-Dependent Initiation of Herpes Simplex Virus Type 1 Infection. Journal of Virology, 2010, 84, 12200-12209.	3.4	48
36	Herpes Simplex Virus Vectors. , 2010, , 69-85.		0

#	Article	IF	Citations
37	Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Review of Neurotherapeutics, 2009, 9, 505-517.	2.8	46
38	Generation of Herpesvirus Entry Mediator (HVEM)-Restricted Herpes Simplex Virus Type 1 Mutant Viruses: Resistance of HVEM-Expressing Cells and Identification of Mutations That Rescue Nectin-1 Recognition. Journal of Virology, 2009, 83, 2951-2961.	3.4	31
39	Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement of virus growth. Virology, 2008, 375, 13-23.	2.4	42
40	Equine Herpesvirus 1 Enters Cells by Two Different Pathways, and Infection Requires the Activation of the Cellular Kinase ROCK1. Journal of Virology, 2007, 81, 10879-10889.	3.4	62
41	Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infection. Virology, 2007, 360, 477-491.	2.4	14
42	Soluble V Domain of Nectin-1/HveC Enables Entry of Herpes Simplex Virus Type 1 (HSV-1) into HSV-Resistant Cells by Binding to Viral Glycoprotein D. Journal of Virology, 2006, 80, 138-148.	3.4	43
43	Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IÎºBÎ± and HSV thymidine kinase. Cancer Gene Therapy, 2005, 12, 487-496.	4.6	25
44	Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. Journal of Gene Medicine, 2005, 7, 638-648.	2.8	33
45	Herpes Simplex Virus Targeting to the EGF Receptor by a gD-Specific Soluble Bridging Molecule. Molecular Therapy, 2005, 11, 617-626.	8.2	44
46	Equine Herpesvirus 1 Utilizes a Novel Herpesvirus Entry Receptor. Journal of Virology, 2005, 79, 3169-3173.	3.4	25
47	Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Molecular Therapy, 2003, 8, 530-542.	8.2	51
48	Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Therapy, 2002, 9, 584-591.	4.5	60
49	Herpesvirus-Mediated Systemic Delivery of Nerve Growth Factor. Molecular Therapy, 2001, 3, 61-69.	8.2	41
50	HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Therapy, 2000, 7, 1483-1490.	4.5	46
51	Connexin 43-Enhanced Suicide Gene Therapy Using Herpesviral Vectors. Molecular Therapy, 2000, 1, 71-81.	8.2	87
52	Effective Treatment of Experimental Glioblastoma by HSV Vector-Mediated TNFÎ± and HSV-tk Gene Transfer in Combination with Radiosurgery and Ganciclovir Administration. Molecular Therapy, 2000, 2, 114-120.	8.2	99
53	Pseudotyping of Glycoprotein D-Deficient Herpes Simplex Virus Type 1 with Vesicular Stomatitis Virus Glycoprotein G Enables Mutant Virus Attachment and Entry. Journal of Virology, 2000, 74, 2481-2487.	3.4	55
54	Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. Journal of Gene Medicine, 1999, 1, 280-289.	2.8	69

#	Article	IF	Citations
55	Genetic Studies Exposing the Splicing Events Involved in Herpes Simplex Virus Type 1 Latency-Associated Transcript Production during Lytic and Latent Infection. Journal of Virology, 1999, 73, 3866-3876.	3.4	23
56	Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Therapy, 1998, 5, 1517-1530.	4.5	152
57	Phenotypic heterogeneity associated with the splicing mutation in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 4081-4088.	3.6	26
58	Suppression of mammalian 5' splice-site defects by U1 small nuclear RNAs from a distance.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 10470-10474.	7.1	40
59	Expression of the H-ras proto-oncogene is controlled by alternative splicing. Cell, 1989, 58, 461-472.	28.9	105
60	A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene. Nature, 1988, 334, 119-124.	27.8	139
61	A repetitive sequence element 3? of the human c-Ha-ras1 gene has enhancer activity. Journal of Cellular Physiology, 1987, 133, 75-81.	4.1	19
62	"Retroposon" insertion into the cellular oncogene c-myc in canine transmissible venereal tumor.. Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 1054-1058.	7.1	118
63	Rearrangement of the oncogene c-mos in mouse myeloma NSI and hybridomas. Nature, 1983, 306, 797-799.	27.8	113
64	Simple DNA sequences in homologous flanking regions near immunoglobulin VHgenes: a role in gene interaction?. Nucleic Acids Research, 1982, 10, 3353-3370.	14.5	112
65	Organization and evolution of immunoglobulin VH gene subgroups.. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 4405-4409.	7.1	123
66	Polymorphism of germ-line immunoglobulin VH genes correlates with allotype and idiotype markers. European Journal of Immunology, 1981, 11, 1017-1020.	2.9	32
67	Diversity of germ-line immunoglobulin VH genes. Nature, 1981, 292, 426-430.	27.8	153
68	Cloning and sequence of the cDNA corresponding to the variable region of immunoglobulin heavy chain MPC11. Nucleic Acids Research, 1980, 8, 3591-3602.	14.5	27
69	Cloning and sequence of the cDNA corresponding to the variable region of immonoglobin heavy chain MPC11. Nucleic Acids Research, 1980, 8, 4839-4839.	14.5	0